Prolyl oligopeptidase stimulates the aggregation of α-synuclein

Peptides

Volumn 29, Issue 9, 2008, Pages 1472-1478

  Brandt, Inger ^a   Gérard, Melanie ^b   Sergeant, Kjell ^c   Devreese, Bart ^c   Baekelandt, Veerle ^b   Augustyns, Koen ^a   Scharpé, Simon ^a   Engelborghs, Yves ^b   Lambeir, Anne Marie ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Amyloid fibrils; Intrinsically unstructured protein; Parkinson's disease; Prolyl oligopeptidase

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; CHYMOTRYPSIN; IMMUNOPHILIN; PEPTIDYLPROLYL ISOMERASE; PROLYL ENDOPEPTIDASE;

ARTICLE; ENZYME ACTIVITY; LEWY BODY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROTITER PLATE ASSAY; PARKINSON DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; TURBIDITY;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; PEPTIDYLPROLYL ISOMERASE; RECOMBINANT PROTEINS; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; SWINE;

ANIMALIA;

EID: 49049103926     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2008.05.005     Document Type: Article

References (50)

1. Avramut M., and Achim C.L. Immunophilins in nervous system degeneration and regeneration. Curr Top Med Chem 3 (2003) 1376-1382
2. Bal G., Van der Veken P., Antonov D., Lambeir A.M., Grellier P., Croft S.L., et al. Prolylisoxazoles: potent inhibitors of prolyloligopeptidase with antitrypanosomal activity. Bioorg Med Chem Lett 13 (2003) 2875-2878
3. Brandt I., De Vriendt K., Devreese B., Van Beeumen J., Van Dongen W., Augustyns K., et al. Search for substrates for prolyl oligopeptidase in porcine brain. Peptides 26 (2005) 2536-2546
4. Brecht S., Schwarze K., Waetzig V., Christner C., Heiland S., Fischer G., et al. Changes in peptidyl-prolyl cis/trans isomerase activity and FK506 binding protein expression following neuroprotection by FK506 in the ischemic rat brain. Neuroscience 120 (2003) 1037-1048
5. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364 (2004) 1167-1169
6. Conway K.A., Harper J.D., and Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med 4 (1998) 1318-1320
7. Feany M.B., and Bender W.W. A Drosophila model of Parkinson's disease. Nature 404 (2000) 394-398
8. Fruitier-Arnaudin I., Cohen M., Coitoux C., and Piot J.M. In vitro metabolism of LVV-Hemorphin-7 by renal cytosol and purified prolyl endopeptidase. Peptides 24 (2003) 1201-1206
9. Gerard M., Debyser Z., Desender L., Kahle P.J., Baert J., Baekelandt V., et al. The aggregation of alpha-synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy. FASEB J 20 (2006) 524-526
10. Gold B.G., Densmore V., Shou W., Matzuk M.M., and Gordon H.S. Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506. J Pharmacol Exp Ther 289 (1999) 1202-1210
11. Gold B.G., Zeleny-Pooley M., Wang M.S., Chaturvedi P., and Armistead D.M. A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration. Exp Neurol 147 (1997) 269-278
12. Gothel S.F., and Marahiel M.A. Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Cell Mol Life Sci 55 (1999) 423-436
13. Guo X., Dawson V.L., and Dawson T.M. Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. Eur J Neurosci 13 (2001) 1683-1693
14. Hagihara M., and Nagatsu T. Post-proline cleaving enzyme in human cerebrospinal fluid from control patients and parkinsonian patients. Biochem Med Metab Biol 38 (1987) 387-391
15. Heukeshoven J., and Dernick R. Characterization of a solvent system for separation of water-insoluble poliovirus proteins by reversed-phase high-performance liquid chromatography. J Chromatogr 326 (1985) 91-101
16. Ibanez P., Bonnet A.M., Debarges B., Lohmann E., Tison F., Pollak P., et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364 (2004) 1169-1171
17. Ichai C., Chevallier N., Delaere P., Dournaud P., Epelbaum J., Hauw J.J., et al. Influence of region-specific alterations of neuropeptidase content on the catabolic fates of neuropeptides in Alzheimer's disease. J Neurochem 62 (1994) 645-655
18. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Schindzielorz A., et al. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci 20 (2000) 6365-6373
19. Kato H., Oikawa T., Otsuka K., Takahashi A., and Itoyama Y. Postischemic changes in the immunophilin FKBP12 in the rat brain. Brain Res Mol Brain Res 84 (2000) 58-66
20. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18 (1998) 106-108
21. Küllertz G., Luthe S., and Fischer G. Semiautomated microtiter plate assay for monitoring peptidylprolyl cis/trans isomerase activity in normal and pathological human sera. Clin Chem 44 (1998) 502-508
22. Laemmi U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
23. Lakso M., Vartiainen S., Moilanen A.M., Sirvio J., Thomas J.H., Nass R., et al. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J Neurochem 86 (2003) 165-172
24. Lauwers E., Debyser Z., Van Dorpe J., De Strooper B., Nuttin B., and Baekelandt V. Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of alpha-synuclein. Brain Pathol 13 (2003) 364-372
25. Li J., Uversky V.N., and Fink A.L. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry 40 (2001) 11604-11613
26. Li W., West N., Colla E., Pletnikova O., Troncoso J.C., Marsh L., et al. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci USA 102 (2005) 2162-2167
27. Lo Bianco C., Ridet J.L., Schneider B.L., Deglon N., and Aebischer P. Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci USA 99 (2002) 10813-10818
28. Mantle D., Falkous G., Ishiura S., Blanchard P.J., and Perry E.K. Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease. Clin Chim Acta 249 (1996) 129-139
29. Mészáros B., Tompa P., Simon I., and Dosztányi Z. Molecular principles of the interactions of disordered proteins. J Mol Biol 372 (2007) 549-561
30. Miyazaki A., Toide K., Sasaki Y., Ichitani Y., and Iwasaki T. Effect of a prolyl endopeptidase inhibitor, JTP-4819, on radial maze performance in hippocampal-lesioned rats. Pharmacol Biochem Behav 59 (1998) 361-368
31. Morain P., Robin J.L., De Nanteuil G., Jochemsen R., Heidet V., and Guez D. Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study. Br J Clin Pharmacol 50 (2000) 350-359
32. Ohama E., and Ikuta F. Parkinson's disease: distribution of Lewy bodies and monoamine neuron system. Acta Neuropathol (Berl) 34 (1976) 311-319
33. Pandey N., Schmidt R.E., and Galvin J.E. The alpha-synuclein mutation E46K promotes aggregation in cultured cells. Exp Neurol 197 (2006) 515-520
34. Polgar L. The prolyl oligopeptidase family. Cell Mol Life Sci 59 (2002) 349-362
35. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
36. Rossner S., Schulz I., Zeitschel U., Schliebs R., Bigl V., and Demuth H.U. Brain prolyl endopeptidase expression in aging, APP transgenic mice and Alzheimer's disease. Neurochem Res 30 (2005) 695-702
37. Russell R.B., and Gibson T.J. A careful disorderliness in the proteome: sites for interaction and targets for future therapies. FEBS Lett 582 (2008) 1271-1275
38. Schulz I., Zeitschel U., Rudolph T., Ruiz-Carrillo D., Rahfeld J.U., Gerhartz B., et al. Subcellular localization suggests novel functions for prolyl endopeptidase in protein secretion. J Neurochem 94 (2005) 970-979
39. Shinoda M., Miyazaki A., and Toide K. Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and on cholinergic and peptidergic neurons in rats with ibotenate-induced lesions of the nucleus basalis magnocellularis. Behav Brain Res 99 (1999) 17-25
40. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
41. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., and Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95 (1998) 6469-6473
42. Szeltner Z., Renner V., and Polgar L. Substrate- and pH-dependent contribution of oxyanion binding site to the catalysis of prolyl oligopeptidase, a paradigm of the serine oligopeptidase family. Protein Sci 9 (2000) 353-360
43. Tarrago T., Sabido E., Kogan M.J., de Oliveira E., and Giralt E. Primary structure, recombinant expression and homology modelling of human brain prolyl oligopeptidase, an important therapeutic target in the treatment of neuropsychiatric diseases. J Pept Sci 11 (2005) 283-287
44. Trojanowski J.Q., and Lee V.M. Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia. Arch Neurol 55 (1998) 151-152
45. Uversky V.N., Li J., and Fink A.L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem 276 (2001) 10737-10744
46. Weinreb P.H., Zhen W., Poon A.W., Conway K.A., and Lansbury Jr. P.T. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35 (1996) 13709-13715
47. Wilk S., and Orlowski M. Inhibition of rabbit brain prolyl endopeptidase by N-benzyloxycarbonyl-prolyl-prolinal, a transition state aldehyde inhibitor. J Neurochem 41 (1983) 69-75
48. Wood S.J., Wypych J., Steavenson S., Louis J.C., Citron M., and Biere A.L. alpha-Synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 274 (1999) 19509-19512
49. Xin H.B., Timerman A.P., Onoue H., Wiederrecht G.J., and Fleischer S. Affinity purification of the ryanodine receptor/calcium release channel from fast twitch skeletal muscle based on its tight association with FKBP12. Biochem Biophys Res Commun 214 (1995) 263-270
50. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55 (2004) 164-173